Eculizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Eculizumab and local guidelines before prescribing.
Mechanism
Complement C5 inhibitor.
Uses
Paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, myasthenia gravis (refractory), NMOSD.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Meningococcal infection, infusion reactions, headache.
Interactions
Few; other immunosuppressants add infection risk.
Contraindications and cautions
Unresolved Neisseria meningitidis infection, no meningococcal vaccination
Monitoring
Infection signs, haemolysis markers
Pregnancy and breastfeeding
Avoid unless essential
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Meningococcal vaccination at least 2 weeks before and antibiotic prophylaxis; patient alert card.
More from the textbook: uses, cautions and other points
- Other targeted drugs (specialist) - basiliximab (induction), belatacept, plasma exchange (anti-GBM disease), avacopan (complement C5a receptor blocker in ANCA vasculitis - liver monitoring), eculizumab (atypical HUS - meningococcal vaccination ), targeted-release budesonide (IgA nephropathy).
Renal: Anatomy, Physiology and Pharmacology - Complement inhibitors - eculizumab and ravulizumab (C5), pegcetacoplan (C3), iptacopan (factor B) - PNH and atypical HUS; meningococcal vaccination (and often antibiotic prophylaxis) is essential - high risk of meningococcal infection.
Haematology: Anatomy Physiology and Pharmacology - Newer targeted drugs (specialist) - complement inhibitors (eculizumab, ravulizumab, zilucoplan - meningococcal vaccination needed) and FcRn blockers (efgartigimod, rozanolixizumab).
Neurology: Anatomy, Physiology and Pharmacology - Newer targeted drugs: inebilizumab (anti-CD19), satralizumab (anti-IL-6 receptor), eculizumab and ravulizumab (complement inhibitors - need meningococcal vaccination).
Neurology: Multiple Sclerosis and inflammatory disease - Inebilizumab / satralizumab / eculizumab | AQP4-positive NMOSD; eculizumab needs meningococcal vaccination.
Neurology: Multiple Sclerosis and inflammatory disease - Long-term prevention (rituximab, inebilizumab, satralizumab or eculizumab).
Neurology: Multiple Sclerosis and inflammatory disease - Refractory disease: Rituximab (especially MuSK); newer treatments - complement inhibitors (eculizumab, ravulizumab, zilucoplan - meningococcal vaccination needed) and FcRn blockers (efgartigimod, rozanolixizumab). Access through specialist centres varies.
Neurology: Neuromuscular disease - Eculizumab / efgartigimod | Refractory generalised MG (complement and FcRn inhibitors); meningococcal vaccination for complement inhibitors.
Neurology: Neuromuscular disease
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (1 mention)
- Neurology: Multiple Sclerosis and inflammatory disease (3 mentions)
- Neurology: Neuromuscular disease (2 mentions)
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)
- Haematology: Emergencies (3 mentions)
- Haematology: Anaemia (2 mentions)
- Paediatrics: Kidneys, urinary tract and hormones in children (2 mentions)
- Rheumatology: Emergencies, pregnancy and other systemic diseases (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (2 mentions)
- Clinical Immunology: Immune system basics and immunological investigations (1 mention)
- Clinical Immunology: Primary immunodeficiency (1 mention)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (6 mentions)
- Clinical Immunology: Autoimmunity, autoantibodies and complement (4 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (3 mentions)
- Integrated paediatrics chapter (2 mentions)
- Microbiology: Bacteriology - structure, classification and important pathogens (1 mention)
- Pathology: Immunopathology, amyloidosis, genetic and environmental disease (2 mentions)